TY - JOUR
T1 - Hyperhomocysteinemia induces renal hemodynamic dysfunction
T2 - Is nitric oxide involved?
AU - Fischer, Patricia A.
AU - Dominguez, Graciela N.
AU - Cuniberti, Luis A.
AU - Martinez, Verónica
AU - Werba, José P.
AU - Ramirez, Agustín J.
AU - Masnatta, Lucas D.
PY - 2003/3/1
Y1 - 2003/3/1
N2 - Hyperhomocysteinemia is associated with endothelial dysfunction, although the underlying mechanism is unknown. Previous studies have shown that nitric oxide (NO) plays an important role in the regulation of systemic and renal hemodynamics. This study investigated whether hyperhomocysteinemia induces renal oxidative stress and promotes renal dysfunction involving disturbances of the NO-pathway in Wistar rats. During 8 wk, control (C) and hyperhomocysteinemic (HYC) groups had free access to tap water and homocysteine-thiolactone (HTL, 50 mg/kg per d), respectively. At 8 wk, plasma homocysteine concentration, renal superoxide anion (O
2), nitrotyrosine, and nitrite+nitrate levels, and renal function were measured. To assess NO involvement, the responses to L-Arginine (L-Arg, 300 mg/kg) and N
G-nitro-L-arginine-methyl-ester (L-NAME, 20 μg/kg per min for 60 min) were analyzed. The HYC group showed higher homocysteine concentration (7.6 ± 1.7 versus 4.9 ± 1.0 μmol/L; P > 0.001), (O
2; production (157.92 ± 74.46 versus 91.17 ± 29.03 cpm · 10
3/mg protein), and nitrite+nitrate levels (33.4 ± 5.1 versus 11.7 ± 4.3 μmol/mg protein; P <0.001) than the control group. Western blot analyses showed a nitrotyrosine mass 46% higher in the HYC group than in the controls. Furthermore, the HYC group showed lower GFR, renal plasma flow (RPF), and higher renal vascular resistance (RVR) than the controls. After L-Arg administrafion, the responses of GFR, RPF, and RVR were attenuated by 36%, 40%, and 50%, respectively; after L-NAME, the responses of RPF and RVR were exaggerated by 79% and 112%, respectively. This suggests a reduced NO bioavailability to produce vasodilation and an enhanced sensitivity to NO inhibition. In conclusion, hyperhomocysteinemia induces oxidative stress, NO inactivation, and renal dysfunction involving disturbances on the NO-pathway.
AB - Hyperhomocysteinemia is associated with endothelial dysfunction, although the underlying mechanism is unknown. Previous studies have shown that nitric oxide (NO) plays an important role in the regulation of systemic and renal hemodynamics. This study investigated whether hyperhomocysteinemia induces renal oxidative stress and promotes renal dysfunction involving disturbances of the NO-pathway in Wistar rats. During 8 wk, control (C) and hyperhomocysteinemic (HYC) groups had free access to tap water and homocysteine-thiolactone (HTL, 50 mg/kg per d), respectively. At 8 wk, plasma homocysteine concentration, renal superoxide anion (O
2), nitrotyrosine, and nitrite+nitrate levels, and renal function were measured. To assess NO involvement, the responses to L-Arginine (L-Arg, 300 mg/kg) and N
G-nitro-L-arginine-methyl-ester (L-NAME, 20 μg/kg per min for 60 min) were analyzed. The HYC group showed higher homocysteine concentration (7.6 ± 1.7 versus 4.9 ± 1.0 μmol/L; P > 0.001), (O
2; production (157.92 ± 74.46 versus 91.17 ± 29.03 cpm · 10
3/mg protein), and nitrite+nitrate levels (33.4 ± 5.1 versus 11.7 ± 4.3 μmol/mg protein; P <0.001) than the control group. Western blot analyses showed a nitrotyrosine mass 46% higher in the HYC group than in the controls. Furthermore, the HYC group showed lower GFR, renal plasma flow (RPF), and higher renal vascular resistance (RVR) than the controls. After L-Arg administrafion, the responses of GFR, RPF, and RVR were attenuated by 36%, 40%, and 50%, respectively; after L-NAME, the responses of RPF and RVR were exaggerated by 79% and 112%, respectively. This suggests a reduced NO bioavailability to produce vasodilation and an enhanced sensitivity to NO inhibition. In conclusion, hyperhomocysteinemia induces oxidative stress, NO inactivation, and renal dysfunction involving disturbances on the NO-pathway.
UR - http://www.scopus.com/inward/record.url?scp=0037372745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037372745&partnerID=8YFLogxK
U2 - 10.1097/01.ASN.0000053419.27133.23
DO - 10.1097/01.ASN.0000053419.27133.23
M3 - Article
C2 - 12595501
AN - SCOPUS:0037372745
VL - 14
SP - 653
EP - 660
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
SN - 1046-6673
IS - 3
ER -